L. crispatus vs. L. iners: Why Vaginal Species Matter

"Lactobacillus" is a genus, not a verdict. In the vagina, Lactobacillus crispatus and Lactobacillus iners can both dominate a microbial community and both make lactic acid. Yet researchers classify them into different community state types: CST I for L. crispatus, CST III for L. iners. Those states track differently with vaginal stability and dysbiosis.

The practical question is whether a product can move someone from a less stable state to CST I. A 2025 randomized pilot trial reported an eye-catching result: among 19 analyzable participants with baseline non-CST-I dysbiosis, a vaginal L. crispatus-based synbiotic converted 90% to CST I by Day 21, versus 11% with placebo (p<0.002). That is proof that targeted vaginal colonization can happen. It is not proof that the product prevents pelvic inflammatory disease (PID), sexually transmitted infections, or every recurrence of bacterial vaginosis.

Species identity changes the question

CST I is L. crispatus-dominant. CST III is L. iners-dominant. CST IV generally describes a more diverse, low-Lactobacillus community often associated with dysbiosis. This taxonomy matters because counting Lactobacillus alone can hide the distinction a consumer actually needs to know.

L. crispatus has a credible antimicrobial rationale. In a laboratory study, cell-free supernatants from L. crispatus inhibited multidrug-resistant urogenital pathogens including Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecalis. That experiment supports biological plausibility, not a human clinical benefit: a cell-free supernatant in a lab dish is not a vaginal treatment trial. The study also did not isolate the active ingredient; lactic acid, hydrogen peroxide, bacteriocins, and other factors remain possible contributors. See Scillato et al.'s in vitro study.

The popular explanation focuses on lactic-acid isomers: L. crispatus is often described as a D(-)-lactic-acid producer, while L. iners is described as producing predominantly L(+)-lactic acid. The distinction is biologically plausible, but the clinical trials discussed here do not prove that D(-) lactic acid itself drives antimicrobial protection. They did not isolate isomer-specific effects against vaginal pathogens. Treat that proposed mechanism as a hypothesis, not a purchasing shortcut with a lab coat.

A vaginal synbiotic changed CSTs in a small trial

In the 2025 Phase 1–2 randomized, placebo-controlled trial of VS-01, 70 participants were assigned across several study arms. The primary CST-conversion analysis in Part A included 19 analyzable participants with baseline dysbiosis. By Day 21, 90% of those receiving the vaginal tablet reached CST I, compared with 11% receiving placebo (p<0.002). The trial found no significant CST I conversion with oral formulations, including formulations containing the same VS-01 strains.

Across Parts A and B, involving 39 participants, VS-01 also reduced Gardnerella vaginalis, Candida species by 236-fold, sialidase-producing gene abundance, and the inflammatory cytokine IL-1α at Day 21. Each reduction met the trial's reported significance threshold: p<0.05 for the microbial and sialidase outcomes and p<0.01 for IL-1α. These are useful secondary findings, but they remain microbiome and biomarker endpoints rather than evidence that participants avoided infection or other clinical disease.

The effect also faded for some participants. Sixty-six percent of Day 21 converters remained in CST I at both Day 35 and Day 51. The reported sustained conversion rate at post-dosing time points was 54.6%, significantly greater than placebo (p<0.02). Follow-up ended at Day 51, only 30 days after dosing stopped. A product that requires maintenance can still be useful; the data simply do not support calling it a permanent microbiome reset. Read the full Ravel et al. VS-01 trial.

LACTIN-V supports colonization, with a different population and endpoint

A separate Phase 2 randomized trial tested the single-strain vaginal live biotherapeutic LACTIN-V, containing L. crispatus CTV-05, in 146 South African women at high risk of HIV acquisition. Colonization reached up to 84% during active dosing. The intervention also reduced pro-inflammatory cervical cytokines and activated CD4+ T cells, findings relevant to HIV susceptibility because activated target cells can increase vulnerability to infection.

That study independently supports the idea that vaginally delivered L. crispatus can colonize and alter inflammatory markers. It does not establish that the same effect size, microbiome response, or clinical implication applies in routine gynecologic care in the United States or Europe. Baseline CST I prevalence was substantially lower in this population than in North American cohorts. The authors also discuss prior U.S. Phase 2b evidence of lower bacterial-vaginosis recurrence three months after treatment stopped, but that is a different trial and endpoint from CST I conversion. See the Hemmerling et al. LACTIN-V trial.

L. iners-dominant communities deserve attention for a separate reason: after antibiotic treatment, they showed high transition rates back toward bacterial communities resembling bacterial vaginosis in the LACTIN-V report. That pattern fits the view of CST III as less stable than CST I. It does not prove that every person with L. iners has disease, nor does it identify one molecular cause of instability.

The PID question remains open

The most relevant prospective test of the protection claim did not find a statistically significant association. In the UK POPI cohort, researchers analyzed 106 young women exposed to chlamydia: 23 developed PID and 83 did not. They identified L. iners-dominant, L. crispatus-dominant, and Gardnerella vaginalis-dominant clusters. Relative abundance of D(-)-lactic-acid-producing Lactobacillus species—combined L. crispatus, L. jensenii, and L. gasseri—was not significantly associated with PID diagnosis.

This null result limits any claim that L. crispatus causally prevents PID. It was also imprecise: contamination exclusions reduced the PID case count from a planned 37 to 23, and samples had been stored for roughly 18 years before sequencing. Those limitations make the result inconclusive, not supportive of the protection hypothesis. The appropriate conclusion is that human PID prevention remains unproven. Read the Kerry-Barnard et al. prospective cohort study.

Oral products have not settled the issue

VS-01's oral arms did not significantly convert participants with baseline dysbiosis to CST I. But oral probiotics cannot be written off as a category. In a 12-week randomized trial, 101 reproductive-age women with Nugent scores of 4–6 received oral MED-01 or placebo; 76 completed the study, and MED-01 significantly reduced Nugent scores versus placebo. Vaginal Lactobacillus plantarum increased while several bacteria associated with dysbiosis declined. That study used different strains and an outcome different from CST I conversion, so it does not contradict VS-01 as neatly as marketing copy would like.

Likewise, a small 2024 trial reported that both oral and vaginal probiotic administration reduced bacterial-vaginosis recurrence after metronidazole, while a 2025 randomized trial of oral L. crispatus M247 reported an association with high-risk HPV clearance and CST shift. Differences in strains, participants, dosing duration, and endpoints may explain why these studies do not line up. No current result justifies assuming that an oral capsule will reproduce a vaginal product's CST I conversion. See the MED-01 trial, the oral-versus-vaginal BV recurrence trial, and the M247 trial.

What to do with this evidence

If the goal is to change vaginal microbiome composition, the best direct evidence here favors a vaginal product that specifies L. crispatus rather than a generic "Lactobacillus" label. The 90% Day 21 conversion result is compelling proof of concept, yet it came from only 19 analyzable participants in the primary analysis, and one-third of early converters did not remain in CST I through Day 51.

A species-specific vaginal intervention can move the microbiome toward CST I. Whether that shift prevents PID, produces durable protection, or depends on a particular lactic-acid isomer remains unanswered.

For recurrent BV or persistent symptoms, use this evidence as a reason to discuss species-specific, vaginally delivered options with a clinician—not as a reason to self-diagnose from a probiotic label. The science has moved beyond "more Lactobacillus is better." It has not yet earned the stronger promise that one species can reliably prevent disease.